Silexion Therapeutics Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLXNW research report →
Price Chart
About the company
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor.
- CEO
- Ilan Hadar
- IPO
- 2024
- Employees
- 14
- HQ
- Jerusalem, TA, IL
Get TickerSpark's AI analysis on SLXNW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $39.75K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.08
- EV/EBITDA
- 0.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -895.97%
- ROIC
- 291.59%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $11.63M
- Net Income
- $-11,912,000+27.6%
- EPS
- $-2150.40+97.7%
- OCF Growth
- -28.9%
- FCF Growth
- -28.6%
- 52W High
- $0.15
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.02
- Beta
- -0.27
- RSI (14)
- 42
- Avg Volume
- 53.25K
No earnings-call transcripts are available for SLXNW yet.
- Free Float
- 100.0%
- Shares Outstanding
- 649.53K
- Float Shares
- 649.53K
of shares held by institutions
21 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Polar Asset Management Partners Inc. | 743.48K | 0 |
| Linden Advisors LP | 337.50K | 0 |
| Clear Street Group Inc. | 217.47K | ▼ 700 |
| Aristeia Capital, L.L.C. | 214.85K | ▼ 21.70K |
| Security Benefit Life Insurance Co | 150.00K | 0 |
| Goldman Sachs Group Inc | 123.03K | ▼ 2.07K |
| Kepos Capital LP | 100.00K | 0 |
| Susquehanna International Group, Llp | 92.07K | ▲ 92.07K |
| Jane Street Group, LLC | 74.91K | 0 |
| Picton Mahoney Asset Management | 57.17K | 0 |
| Context Capital Management, LLC | 51.18K | 0 |
| Tenor Capital Management Company, L.P. | 50.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 4, 26 | Shirvan Mitchell | other | 6,000 |
| Jun 4, 26 | Horenshtein Hadar Mirit | other | 7,500 |
| Jun 4, 26 | Hadar Ilan | other | 10,000 |
| Mar 26, 26 | Shirvan Mitchell | sell | 22,818 |
| Feb 20, 26 | Noy Shlomo | other | 9,091 |
| Feb 20, 26 | Noy Shlomo | other | 10,685 |
| Feb 20, 26 | Alon Ruth | other | 10,685 |
| Feb 20, 26 | Alon Ruth | other | 9,091 |
| Feb 20, 26 | Shirvan Mitchell | other | 49,726 |
| Feb 20, 26 | Horenshtein Hadar Mirit | other | 49,726 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SLXNW coverage
Recent articles, reports, and earnings notes.
No research on SLXNW yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SLXNW report →